摘要
目的 :研究头孢克洛分散片在健康人体内的药物动力学与相对生物利用度。方法 :采用高效液相色谱法测定 10名健康自愿者单剂量口服 5 0 0mg头孢克洛分散片和胶囊后的血药浓度变化情况 ,计算两者的药物动力学参数及相对生物利用度。结果 :10名健康志愿者药时曲线均符合一室模型 ,头孢克洛分散片和胶囊剂的Tmax分别为 (40 4± 4 8)和 (44 5± 6 2 )min ,Cmax分别为 (8 2± 1 2 )和 (97 0± 0 7) μg/ml,t1/ 2 分别为 (35 3± 8 5 )和(38 0± 5 8)min ,AUC分别为 (86 8 2± 5 5 2 )和 (879 7± 10 9 2 ) (μg·min) /ml,片剂对胶囊剂的相对生物利用度F为 (99 4± 6 8) % (87 0 %～ 10 5 1% )。结论
OBJECTIVE: To study the pharmacokinetics and relative bioavailability of cefaclor tablet and capsule METHODS: The study was conducted in ten healthy volunteers After receiving a single dose of 500 mg cefaclor tablet or capsule, the blood drug concentrations were determined by HPLC and the pharmacokinetic parameters and relative bioavailability were calculated RESULTS: The concentration time curves obtained are in line with 1 compartment model The pharmacokinetic parameters for tablet and for capsule are as follows: T max :(40 4±4 8) and (44 5±6 2) min,C max : (8 2±1 2) and (97 0±0 7)μg/ml, t 1/2 : (35 3±8 5) and (38 0±5 8) min,AUC 0→∞ : (868 2±55 2) and (879 7±109 2) (μg·min)/ml The relative bioavailability for tablet is (99 4±6 8)% (87 0%～105 1 %) compared with capsule CONCLUSION: Cefaclor tablet and capsule are bioequivalent
出处
《中国新药杂志》
CAS
CSCD
2000年第2期103-104,108,共3页
Chinese Journal of New Drugs
